Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Exploratory Study to Evaluate The Preliminary Efficacy of GH21 Combined With Primary Targeting or Immunotherapy in Patients With Advanced Solid Tumors Which Targeted or Immunotherapy Has Progressed

NCT06322095 is registered in ClinicalTrials.gov with Suzhou Genhouse Bio Co., Ltd. as lead sponsor.

NCT NCT06322095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06322095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Exploratory Study to Evaluate The Preliminary Efficacy of GH21 Combined With Primary Targeting or Immunotherapy in Patients With Advanced Solid Tumors Which Targeted or Immunotherapy Has Progressed
Lead sponsor
Suzhou Genhouse Bio Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
March 22, 2024
Completion date
December 31, 2025
Enrollment
72 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor with oncogenic driver mutations, patients with advanced solid tumor